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THE IMPACT OF METHYLENETETRAHYDROFOLATE REDUCTASE C677T
GENE POLYMORPHISM ON ENGRAFTMENT AFTER ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION IN PATIENTS RECEIVING METH-
OTREXATE IN GRAFT VERSUS HOST DISEASE PROPHYLAXIS
Arat, M.1, Soydan, E.1, Topcuoglu, P.1, Ozcan, M.1, Arslan, O.1,
Gurman, G.1, Ilhan, O.1 1Ankara University Medical School, Hema-
tology Department, BMT Unit, Ankara, Turkey.
Methotrexate (MTX) is an antifolate chemotherapeutic drug and
is used to prevent graft versus host disease (GVHD) in allogeneic
hemapoietic cell transplantation (AHCT). The effectiveness of
MTX is largely attributable to its role of MTHR and its gene
polymorphism is a common (10-12% homozygote and 40% het-
erozygote) variation in the population. Depending on to this ﬁnd-
ing, we investigated whether MTHFR C677T gene polymorphism
has any affect on engraftment kinetics of patients undergoing
ASCT to whom MTX is given for GVHD prophylaxis. We ret-
rospectively analyzed our cohort of 82 allogeneic stem cell recip-
ients whose MTHFR gene polymorphism of C677T region was
analyzed by RT-PCR for the pretransplant evaluation of hereditary
thrombophilia. The patient’s median age was 31 (range, 14-50)
years, with a M/F: 50/32 and diagnosis; 35 AML, 26 CML, 12 ALL
and 9 other. Nearly all of the patients were given standard condi-
tioning regimen consisting of BUCY or TBICY. All of the patients
received cyclosporine A and short term MTX for GVHD prophy-
laxis. Stem cell source was bone marrow (BM) in 23 and peripheral
blood (PB) in 59 of the patients. MTHFR gene polymorphism was
detected in 32 (39%) of all patients, and 90% were heterozygotes
(MTHFR HeZ). When we compared the engraftment kinetics,
granulocyte engraftment was found to be late in MTHFR HeZ
group (neutrophil 1000 median 19 vs 17 days; P  .01) but not
different for neutrophil 500 and platelet engraftment. We have
observed that MTHFR gene polymorphism had a prominent effect
on BM recipients, as both neutrophil 500 and 1000 and also
platelet engraftments were affected (granulocyte 500 median 21 vs
15 P .005; granulocyte 1000 median 22.5 vs 17 P .0001 and plt
20 median 27 vs 21 P  .03) signiﬁcantly. On the contrary, there
was no difference in the PB group. The number of MNC and
CD34 cells were similar in patients with and without gene poly-
morphism both in BM and PG group. When we compare the side
effects of MTX such as nausea and vomiting, diarrhea, mucositis,
there was no difference in acute GVHD incidence. Our knowledge
on epigenetic data will help us on tailoring the chemotherapy
regimen for conditioning and GvHD prophylaxis in transplant
recipients. Our data on a limited patient size suggest that the
presence of MTHFR HeZ may have an impact on allo HCT
recipients engraftment kinetics while using MTX for GVHD pro-
phylaxis and BM as stem cell source.
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SIROLIMUS AND TACROLIMUS WITHOUT METHOTREXATE AS GRAFT-
VS.-HOST DISEASE PROPHYLAXIS AFTER MATCHED, UNRELATED PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): EXCEL-
LENT GVHD CONTROL WITH LOW TRANSPLANT-RELATED MORBIDITY
AND MORTALITY
Cutler, C.1, Li, S.2, Kim, H.T.2, Macdonell, R.1, Ho, V.1, Alyea, E.1,
Lee, S.J.1, Soiffer, R.1, Antin, J.H.1 1Medical Oncology, Dana-Farber
Cancer Institute, Boston, MA; 2Biostatistics and Computational Biology,
Dana-Farber Cancer Institute, Boston, MA.
We have previously demonstrated that the combination of siroli-
mus (rapamycin, Rap), tacrolimus (Tac) and low-dose methotrex-
ate (Mtx) is effective GVHD prophylaxis in URD transplantation,
and the combination of Rap and Tac alone is effective in MRD
transplantation. Since Mtx is associated with transplant-related
toxicity and delayed engraftment, we hypothesized that Rap and
Tac, without Mtx, would provide effective GVHD prophylaxis in
URD transplantation while minimizing transplant-related morbid-
ity and mortality. Methods: 30 subjects underwent PBSCT from
6/6 HLA-matched unrelated donors after Cy/TBI conditioning.
GVHD prophylaxis consisted of Rap (target serum level 3-12
ng/ml) and Tac (target serum level 5-10 ng/ml). G-CSF (5 g/kg)
was administered from day 12 until engraftment, if needed.
Results: The median age of subjects was 44 years (range 22-54).
Diagnoses were AML (13), CML (6), NHL (4), MDS (3), ALL (2),
MPD (1) and HD (1). The median times to neutrophil (	500/L)
and platelet engraftment (	20000/L and 	100000/L) were
13.5 (range 11-14), 12 (range 9-25), and 17 (range 12-101) days,
respectively. Two patients did not become platelet transfusion
independent. All 30 patients survived to ﬁrst hospital discharge, at
a median of 19 days from day 0 (range 14-55). Gr. II-IV acute
GVHD occurred in 5 patients (16.7%) with only one case of Gr.
IV acute GVHD (3.3%). Transplant-related morbidity was low,
without any cases of IPS/DAH. Two subjects developed VOD and
one subject developed thrombotic microangiopathy. Reactivation
of HHV-6 with limbic encephalitis was noted in 2 patients. 13 of
25 evaluable patients developed chronic GVHD. Five patients
relapsed, one of whom achieved a durable complete remission after
immunosuppression withdrawal and DLI. Causes of death include
relapse (3), VOD (1), and relapse with VOD and hepatic GVHD
(1). The median follow-up is 230 days (range 46-608). Treatment-
related mortality at 100 days is 3.3%. Relapse-free and overall
survival at day 100 are both 93.1%, and at 1 year are 78.1% and
80.9%, respectively. Conclusions: Rap and Tac without Mtx is
effective for GVHD prophylaxis after matched URD PBSCT,
leading to acute GVHD in 16.7% of treated patients, which is
similar to our experience using Rap and Tac in MRD transplan-
tation. Furthermore, the omission of Mtx is associated with min-
imal transplant-related morbidity and mortality at 100 days. This
combination is worthy of broader study in unrelated donor trans-
plantation.
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MEASURING MULTIPLE SYMPTOMS AND INFLAMMATORY CYTOKINES
RELATED TO ACUTE GVHD IN AML/MDS PATIENTS UNDERGOING AL-
LOGENEIC BMT
Giralt, S.1, Cleeland, C.S.1, Reuben, J.1, Lee, B.-N.1, Williams, L.A.1,
Mobley, G.1, Wang, X.S.1 1University of Texas M. D. Anderson Cancer
Center, Houston, TX.
The objective of this study was to prospectively assess the rela-
tionship between symptom severity and changes in inﬂammatory
cytokines around the time of diagnosis of acute GVHD in AML/
MDS patients during the ﬁrst 100 days of allo-BMT. Methods:
Weekly symptom assessment with the M. D. Anderson Symptom
Inventory was done for 30 patients for the ﬁrst 100 days following
BMT. A panel of inﬂammatory cytokines (IL-1ra, IL-6, IL-8,
IL-10, IL-12, TNF-
) was assayed at multiple time points (pre-
BMT, conditioning, day of BMT, BMT day 1, nadir, BMT days
8, 14, 21, 28, 60, and 90-100, also days 1, 3, 5, 10 and
15 of diagnosis of acute GVHD for the 26 patients who developed
it). Results: Of the 26 patients who developed acute GVHD, 69%
had grade 1 GVHD, 27% had grade 2, and 4% had grade 3. 42%
were treated systemically with a dose of 2 mg/kg of steroids, and
31% were treated with topical steroids alone. Non-speciﬁc symp-
toms experienced by these patients reached their highest levels
shortly before the day of diagnosis of acute GVHD. Immediate
symptom reduction occurred after diagnosis of acute GVHD and
was most likely caused by administration of steroids. IL-8 was
signiﬁcantly correlated with some symptoms before and after di-
agnosis of acute GVHD (Table 1). Conclusion: During develop-
ment of GVHD in the acute phase of allo-BMT, there was an
observed relationship of severity of certain symptoms and in-
creased or decreased inﬂammatory cytokine levels in this pilot
5BB&MT
study. Further study is warranted for a causal link between general
sickness and speciﬁc cytokines during human GVHD develop-
ment.
Table 1. Correlations between Symptom Severity and IL-8 Levels
before and after the Development of GVHD in the First 100 Days
after Allo-BMT
Symptom Correlation with IL-8 Levels
Pre-GVHD
Shortness of breath r  0.708, P < .01
Dry mouth r  0.667, P < .05
Sadness r  0.631, P < .05
Post-GVHD
Sleep disturbance r  0.564, P < .05
Drowsiness r  0.565, P < .05
Vomiting r  0.558, P < .05
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INCREASED CLEARANCE OF ASPERGILLUS FUMIGATUS IN MICE WITH
CHRONIC LUNG INJURY AFTER ALLOGENEIC STEM CELL TRANSPLAN-
TATION
Hildebrandt, G.C.1, Olkiewicz, K.2, Hogaboam, C.M.3, Ferrara, J.L.2,
Cooke, K.R.2 1Department of Hematology and Oncology, University of
Regensburg Medical School, Regensburg, Germany; 2Department of Pe-
diatrics, University of Michigan Medical School, Ann Arbor, MI; 3De-
partment of Pathology, University of Michigan Medical School, Ann
Arbor, MI.
Chronic lung injury (CLI) is a frequent problem after allogeneic
(allo) stem cell transplantation (SCT) leading to obstructive and/or
restrictive changes in lung function. CLI is associated with signif-
icant morbidity and mortality and is frequently complicated by
co-existing opportunistic infections. We developed a murine SCT
model of CLI by transplanting splenocytes and bone marrow cells
from G-CSF treated syngeneic (syn) B6D2F1 or allo C57BL/6
donor mice into lethally irradiated B6D2F1 recipients. Animals
were analyzed between day 90 and 100 after transplant. Allo but
not syn recipients showed typical changes of CLI: pulmonary
resistance was signiﬁcantly increased (146 12 vs. 106 5%), and
lung compliance was decreased (62  6 vs. 77  3%) compared to
syn controls (P  .01) Functional changes correlated with signiﬁ-
cant histopathology, including a dense mononuclear cell inﬁltrate
around bronchial structures (score: 5.3  0.7 vs. 0.3  0.3; P 
.01), peribronchial ﬁbrosis and pulmonary collagen deposition.
Histopathologic changes were associated with increased numbers
of BALF total cells (1.68  0.26 vs. 0.89  0.08  106; P  .01),
and both CD4 (2.9  0.4 vs. 1.4  0.1  105; P  .01) and
CD8 T cells (1.0  0.1 vs. 0.1  0.0  105; P  .01). Interest-
ingly, IFN- CD4 and IFN- CD8 T cells and lung mRNA
for CCR2 were also increased indicating a local proinﬂammatory
environment. Next we determined whether animals with CLI after
allo-SCT were more susceptible to fungal infection than syn con-
trols. SCT recipients were injected intratracheally with 5  106
Aspergillus fumigatus (A.f.) conidia around day 70 and were analyzed
3 weeks later. Surprisingly, recipients of allo-SCT showed in-
creased pulmonary clearance of A.f. with signiﬁcant reductions of
conidia within the bronchial epithelium and of associated goblet
cell hyperplasia compared to syn controls. Conclusion: Despite
the development of signiﬁcant CLI, allo-SCT recipients have en-
hanced clearance of A.f. conidia compared to syn controls. These
data suggest that the proinﬂammatory micro-environment associ-
ated with non-infectious lung injury after SCT may have a here-
tofore unidentiﬁed beneﬁcial effect on immune surveillance, per-
haps calling into question the merits of continuing systemic
immunosuppression in patients with CLI without evidence for
clear improvements in lung function.
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DONOR-SPECIFIC CELL ENGRAFTMENT AFTER INTRAOSSEOUS AND
INTRAVENOUS BONE MARROW TRANSPLANTATION
Klimczak, A.1, Unal, S.1, Jankowska, A.1, Coburn, C.1,
Siemionow, M.1 1The Cleveland Clinic Foundation, Cleveland, OH.
Background: Engraftment of donor-derived bone marrow cells
into recipient bone marrow environment can induce hematopoietic
chimerism and tolerance to antigen-matched organs in solid organ
and composite tissue allograft. This study was designed to inves-
tigate the effect of intraosseous bone marrow transplantation
(BMT) for donor cells engraftment into the bone marrow envi-
ronment and lymphoid tissue compartment across MHC barrier
under short-term 
-TCRmAb/CsA protocols. Materials and
Methods: Forty-eight BMT were performed between ACI (RT1a)
donors and LEW (RT1l) recipients. Intraosseous and intravenous
BMT was studied in 6 groups of 8 animals each receiving 35  106
(n  4) and 70  106 (n  4) bone marrow cells. Groups I and II
(controls) received BMT but no treatment, groups III and IV CsA
monotherapy, and groups V, VI 
-TCRmAb/CsA protocol for 7
days. Flow cytometry monitored immunodepletion and donor-
speciﬁc chimerism for MHC class I (RT1a) antigens in the periph-
eral blood and bone marrow compartment. Immunocytochemical
staining was employed to detect the presence of donor-derived
cells in the lymphoid tissue of recipients. Results: All animals
survived without the occurrence of graft versus host disease. Short
term 
-TCRmAb/CsA protocol and 70  106 bone marrow cells
delivery resulted in 7.9%  1.3% of donor cell engraftment after
intraosseous BMT compared to 4.2%  1.4% after intravenous
transplantation. Donor bone marrow cell engraftment into the
recipient bone marrow compartment delivered via the intraosseous
route under the 
-TCRmAb/CsA protocol was 40% more efﬁ-
cient after 70  106 bone marrow cell transplantation compared to
35  106 (7.9% vs 4.8% respectively). Also, CsA monotherapy and
70  106 bone marrow cell delivery resulted in better engraftment
of donor cells after intraosseous transplantation compared to 35 
106 of BMT (3.8% vs 2.2% respectively). Donor-derived cells were
present in the lymph nodes and spleen of recipients. Higher seed-
ing efﬁciency of donor cells into the lymphoid tissue compartment
was achieved after intraosseous BMT and 
-TCRmAb/CsA pro-
tocol compared to standard intravenous transplantation. Conclu-
sion: Intraosseous transplantation of donor bone marrow cells
under 
-TCRmAb/CsA protocol was more effective for donor
cell engraftment into recipients’ bone marrow environment and
lymphoid tissue compartment compared to intravenous transplan-
tation.
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ALLOGENEIC TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA: INTENTION TO TREAT ANALYSIS OF THE EORTC ALL-4
PHASE III TRIAL
Labar, B.1, Suciu, S.2, Muus, P.3, Willemze, R.4, Marie, J.-P.5,
Fillet, G.6, Berneman, Z.7, Jaksic, B.8, Feremans, W.9, Bron, D.10,
Sinnige, H.11, Mistrik, M.12, Vreugdenhil, G.13, De Bock, R.14,
Nemet, D.1, Gilotay, C.2, De Witte, T.3, Amadori, S.15 1University
Hospital Center Rebro, Zagreb, Croatia; 2EORTC Data Center, Brus-
sels, Belgium; 3St. Radboud University Hospital, Nijmegen, The Neth-
erlands; 4Leiden University Hospital, Leiden, The Netherlands; 5Hotel-
Dieu de Paris, Paris, France; 6CHU Sart-Tilman, Liege, Belgium;
7Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium; 8Clinical
Hospital Merkur, Zagreb, Croatia; 9Hopital Universitaire Erasme,
Brussels, Belgium; 10Institut Jules Bordet, Brussels, Belgium; 11Groot
Ziekengasthuis, Den Bosch, Netherlands; 12University Hospital,
Bratislava, Slovakia (Slovak Republic); 13St. Josef Ziekenhuis, Veld-
hoven, The Netherlands; 14Algemeen Ziekenhuis Middelheim, Antwer-
pen, Belgium; 15Ospedale San Eugenio, Rome, Italy.
Results of the EORTC ALL-3 reveal that the policy to perform
allo-SCT in a case when a sibling donor is available does not result
in a signiﬁcantly better outcome than to offer auto-SCT or con-
tinuous maintenance. We also analysed the outcome of allografted
patients in EORTC ALL-4. In this trial patients were randomized
to receive either dexamethasone (10 mg/m2/day) or 6-methyl-
prednisolone (60 mg/m2/day) on days 1-8 and 15-22 with standard
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